Saturday 17 October 2026
Export CELZ’s income statement to Excel — free account
Creative Medical Technology Holdings, Inc.
CELZ Healthcare Biotechnology
Creative Medical Technology Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6,000.00, down 45.5% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 14.6% and free cash flow fell 27.1%, each against the same quarter a year earlier.
0.74
0.08
−9.76%
Follow CELZ
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | 0.00 | — | — |
P/S ratio |
— | 274.72 | — | — | |
P/FCF ratio |
— | 0.00 | — | — | |
P/Operating CF |
— | (2.41) | — | — | |
P/B ratio |
— | 0.62 | — | — | |
Price to Tangible BV |
— | 0.66 | — | — | |
EV/Sales |
— | (142.33) | — | — | |
EV/EBITDA |
— | 0.40 | — | — | |
EV/Operating CF |
— | 0.41 | — | — | |
EV/FCF |
— | 0.22 | — | — | |
Quick Ratio |
20.56 | 25.30 | 19.01 | 12.65 | |
Current Ratio |
20.70 | 25.97 | 19.70 | 12.91 | |
Net Debt/EBITDA |
4.33 | 3.76 | 4.08 | 5.73 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.95 | 1.03 | 0.94 | 0.97 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
34.31 | — | — | 30.69 | |
Research and Development Expense of Revenue |
0.00% | 18,336.67% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 45,560.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.07 | 0.05 | 0.06 | 0.04 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | — | |
Graham Net Nets |
— | 1.52 | — | — | |
Graham Number |
— | 0.00 | — | — | |
Earnings Yield |
— | (132.14%) | — | — | |
Free Cash Flow Yield |
— | (239.34%) | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.45) | (0.81) | (0.36) | (0.40) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.45) | (0.81) | (0.36) | (0.40) | |
Cash per Share |
2.08 | 3.03 | 1.58 | 2.39 | |
Shareholders Equity per Share |
2.17 | 3.16 | 1.66 | 2.34 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.17 | 3.16 | 1.66 | 2.34 | |
Free Cash Flow |
(1.17) | (1.94) | (1.32) | (1.47) | |
Working Capital |
5.15 | 7.11 | 5.75 | 8.32 | |
Net Current Asset Value |
5.15 | 7.11 | 5.75 | 8.32 | |
EV/EBIT |
— | 0.39 | — | — | |
Capex to Sales |
— | 0.00 | — | — | |
Price to Operating Income |
— | 0.00 | — | — | |
| Other line items | |||||
Average Payables |
0.26 | 0.27 | 0.28 | 0.47 | |
Average Inventory |
0.00 | — | — | — | |
Average Assets |
6.37 | 7.24 | 7.39 | 8.24 | |
Average Common Equity |
6.07 | 6.93 | 7.10 | 7.75 |
Columns are period end dates